![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
OSLO, Norway, Sept. 09, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical firm devoted to the invention and growth of novel immunotherapies, at this time introduced that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete Fredriksen, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 11:00 a.m. ET / 5:00 p.m. CET and can be found for 1:1 investor conferences.
The dwell and archived webcast of the presentation might be accessed within the Investors part of the Company’s web site right here.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical firm devoted to the invention and growth of novel immunotherapies for the remedy of most cancers and infectious illnesses. Nykode’s modular vaccine expertise particularly targets antigens to Antigen Presenting Cells, that are important for inducing fast, robust and long-lasting antigen particular immune responses and eliciting efficacious scientific responses.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the remedy of human papilloma virus (HPV)-16 induced malignancies which demonstrated constructive interim efficacy and security outcomes from its Phase II trial for the remedy of cervical most cancers; and VB10.NEO, an individualized most cancers neoantigen vaccine, which is completely out-licensed to Genentech, a member of the Roche Group, and is in Phase 1b for the remedy of regionally superior and metastatic tumors and Phase 1/2a for the remedy of melanoma, lung-, head and neck, renal-, and bladder most cancers. Additionally, Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.
The Company’s partnerships embody Genentech inside oncology, a multi-target collaboration with Regeneron inside oncology and infectious illnesses and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine growth.
Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further details about Nykode Therapeutics could also be discovered at http://www.nykode.com.
Contact for Nykode Therapeutics ASA:
Chief Business Officer, Agnete Fredriksen
Nykode Therapeutics ASA
[email protected]
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
Forward-looking statements for Nykode Therapeutics
This announcement and any supplies distributed in reference to this announcement could include sure forward-looking statements. By their nature, forward-looking statements contain danger and uncertainty as a result of they replicate the corporate’s present expectations and assumptions as to future occasions and circumstances that will not show correct. A variety of materials elements might trigger precise outcomes and developments to differ materially from these expressed or implied by these forward-looking statements.
